Corporate
Mar. 25, 2016
Slowing capital markets spur more inside participation in IPOs
According to a recent report from Renaissance Capital LLC, a firm tracking IPOs, inside investors bought up nearly fifty percent of public company stock in five biotech IPOs this year.
Daily Journal Staff Writer
After a healthy three-year period that saw a steady pipeline of public offerings, early signs in the 2016 biotechnology market point to an increase of insider investment in IPOs amid softening public interest in the sector.
According to a recent report from Renaissance Capital LLC, an IPO data tracking firm, inside investors - board members, their affiliated funds and ev...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In